A Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

• Status: Recruiting
• Trial end date: 2027-01-14
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Genentech, Inc.

Criteria

Inclusion Criteria:

• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1

• Life expectancy of at least 12 weeks

• Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody.

• Documented evidence of progressive disease on or after the last prior therapy, or participants who were intolerant to the last prior therapy.

• Measurable disease, as defined by the protocol

• Participants agree to follow contraception or abstinence requirements as defined in the protocol

Exclusion Criteria:

• Any anti-cancer therapy within 3 weeks prior to initiation of study treatment with exception defined by the protocol

• Participants with autologous stem cell transplantation (SCT) within 100 days prior to first dose of study treatment

• Participants with prior allogeneic SCT or solid organ transplantation

• Active or history of autoimmune disease

• Participants with current or history of Central Nervous System (CNS) disease, or current CNS involvement by Multiple Myeloma (MM)

• Significant cardiovascular disease

• Participants with known clinically significant liver disease

• Symptomatic active pulmonary disease requiring supplemental oxygen

• Known active infection requiring intravenous anti-microbial therapy within 14 days prior to first study drug administration

• Other protocol defined inclusion/exclusion criteria may apply